|
The following trials are currently closed for Enrollment but Ongoing :
1. Oral Fingolimod Trial EPOC Study ( Novartis Pharmaceuticals Corporation)
- A 6- month, randomized, Active Comparator, Open-Label, Multi-center study to evaluate Patient outcomes, safety
and tolerability of Fingolimod (FTY720) 0.5mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates
for MS therapy change from Previous Disease Modifying Therapy.
2. Safer Monitoring For Tysabri Patients
MS Center of Northeastern NY of Empire Neurology is
taking part in this study for monitoring the safety of TYSABRI.
(a) RESTORE STUDY: This study is
an organized withdrawal for 6 months from Tysabri for patients on Tysabri for more than 12 months. It is a randomized study
where 1/4 of patients stay on Tysabri, 1/4 go off Tysabri and 1/2 go on other medications. Patients get monthly MRI and blood
tests. No one knows if 6 months withdrawl from Tysabri increase risk of PML or not. This study will scientifically analyze
this question. Antibodies, cytokines and other markers for disease activity will be monitored.
(b)STRATIFY-2 JCV STUDY: The
Stratify-2 study will test multiple sclerosis (MS) patients to determine if they have a specific antibody in their blood against
the JC virus (JCV). The purpose of the STRATIFY-2 is to gather more information about MS patients being treated with TYSABRI
or who are considering Tysabri have the JCV antibody in their blood or not. This will allow better understanding whether antibodies
to JCV may be used to predict whether a patient is at a higher or lower risk for developing PML.
3. Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy
and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting
Multiple Sclerosis ( 205MS301 - Biogen Idec)
Click here for more information on clinicaltrials.gov
4. Clinical Study using Oral Drug in Patients
with Relapsing Remitting Multiple Sclerosis (RRMS)
MS Center of Northeastern NY of Empire Neurology
is taking part in a research program for the development of an oral drug for disease modification for patients with Relapsing
Remitting Multiple Sclerosis. Attached is the advertisement for the trial and links to the clinical.gov site for study details.
CLICK HERE TO DOWNLOAD ADVERTISEMENT FOR TRIAL
Click here for more information about the study from Clinical.gov website
5. ECF1053 THE TOWER STUDY (Sanofi Aventis)
- A multi-center, double-blind, parallel-group, placebo-controlled
study of the efficacy and safety of teriflunomide in patients with relapsing MS.
Click here for more Information on Tower Study
|
